Department of Epidemiology and Biostatistics, School of Public Health, Tehran University Medical, Tehran, Iran; Tuberculosis/HIV Research Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University Medical, Tehran, Iran; Departiment of Internal Medicine, Shifa Complex Hospital, Gaza, Palestine.
Int J Infect Dis. 2020 Jul;96:12-18. doi: 10.1016/j.ijid.2020.03.064. Epub 2020 Apr 11.
We aimed to compare and contrast the proportions of treatment outcome between developing and developed countries in children treated for multidrug resistance tuberculosis (MDR-TB).
We conducted a systematic review and meta-analysis of articles published on children treated for MDR-TB. We searched published articles from electronic databases: PubMed/Medline, EMBASE, Scopus and Web of Science for English articles without restricting publication year. We employed random-effects meta-analysis model to estimate the pooled proportions of treatment success, death, treatment failure and lost to follow up.
We pooled data of 1,343 children obtained from 17 included studies, and the overall pooled treatment success was 77.0% (95% Confidence Interval (CI), 69.0-85.0). Pooled treatment success in developing countries was 73.0% (63.0-83.0), while in developed countries 87.0% (81.0-94.0). The overall pooled treatment failure was 3.0% (1.0-6.0), while death 8.0% (4.0-11.0) and lost to follow up 10.0% (6.0-4).
MDR-TB treatment success in children is well achieved in both developed and developing countries by currently available drugs. Improving MDR-TB treatment programme is vital to achieve the maximum treatment successful. Promoting research on pediatric MDR-TB treatment outcome could also help to fill evidence gap.
本研究旨在比较和对比发展中国家和发达国家在儿童耐多药结核病(MDR-TB)治疗中治疗结局的比例。
我们对发表的关于儿童耐多药结核病治疗的文章进行了系统评价和荟萃分析。我们从电子数据库 PubMed/Medline、EMBASE、Scopus 和 Web of Science 中检索了英文文章,没有限制发表年份。我们采用随机效应荟萃分析模型来估计治疗成功、死亡、治疗失败和失访的合并比例。
我们汇总了 17 项纳入研究中 1343 名儿童的数据,总体治疗成功率为 77.0%(95%置信区间(CI),69.0-85.0)。发展中国家的治疗成功率为 73.0%(63.0-83.0),而发达国家为 87.0%(81.0-94.0)。总体治疗失败率为 3.0%(1.0-6.0),死亡率为 8.0%(4.0-11.0),失访率为 10.0%(6.0-4.0)。
目前可用的药物在发展中国家和发达国家均能很好地实现儿童耐多药结核病的治疗成功。改善耐多药结核病治疗方案对实现最大治疗成功至关重要。促进儿科耐多药结核病治疗结局的研究也有助于填补证据空白。